Effectiveness and safety of ustekinumab for moderate to severely active Crohn’s disease: results from an early access program in Brazil (2022)
- Authors:
- Autor USP: PARRA, ROGÉRIO SERAFIM - FMRP
- Unidade: FMRP
- DOI: 10.3390/jcm11216481
- Subjects: RESULTADO DE TRATAMENTO; PROGRAMA DE ASSISTÊNCIA; DOENÇA DE CROHN
- Keywords: Biological products; Ustekinumab; Crohn’s disease; Early access program
- Language: Inglês
- Imprenta:
- Source:
- Título: Journal of Clinical Medicine
- ISSN: 2077-0383
- Volume/Número/Paginação/Ano: v. 11, n. 21, art. 6481, 2022
- Este artigo possui versão em acesso aberto
- URL de acesso aberto
- PDF de acesso aberto
- Versão do Documento: Versão publicada (Published version)
-
Status: Artigo publicado em periódico de acesso aberto (Gold Open Access) -
ABNT
CHEBLI, Julio Maria Fonseca et al. Effectiveness and safety of ustekinumab for moderate to severely active Crohn’s disease: results from an early access program in Brazil. Journal of Clinical Medicine, v. 11, n. 21, 2022Tradução . . Disponível em: https://doi.org/10.3390/jcm11216481. Acesso em: 15 mar. 2026. -
APA
Chebli, J. M. F., Parra, R. S., Flores, C., Moraes, A. C., Nones, R. B., Gomes, T. N. F., et al. (2022). Effectiveness and safety of ustekinumab for moderate to severely active Crohn’s disease: results from an early access program in Brazil. Journal of Clinical Medicine, 11( 21). doi:10.3390/jcm11216481 -
NLM
Chebli JMF, Parra RS, Flores C, Moraes AC, Nones RB, Gomes TNF, Perdomo AMB, Scapini G, Zaltman C. Effectiveness and safety of ustekinumab for moderate to severely active Crohn’s disease: results from an early access program in Brazil [Internet]. Journal of Clinical Medicine. 2022 ; 11( 21):[citado 2026 mar. 15 ] Available from: https://doi.org/10.3390/jcm11216481 -
Vancouver
Chebli JMF, Parra RS, Flores C, Moraes AC, Nones RB, Gomes TNF, Perdomo AMB, Scapini G, Zaltman C. Effectiveness and safety of ustekinumab for moderate to severely active Crohn’s disease: results from an early access program in Brazil [Internet]. Journal of Clinical Medicine. 2022 ; 11( 21):[citado 2026 mar. 15 ] Available from: https://doi.org/10.3390/jcm11216481 - National registration of patients with inflammatory bowel disease in Brazil on behalf of GEDIIB
- Efeito da oxigenação hiperbárico na colite aguda induzida pelo TNBS. Estudo experimental em ratos
- Regarding “rectal shaving for bowel endometriosis by a laparoscopic reverse submucosal dissection [Carta]: points to be highlighted"
- Long-term follow-up after endometriosis surgery [Carta]: what about deep endometriosis?
- Comment on: Antibiotics as first-line alternative to appendicectomy in adult appendicitis. [Carta]: 90-day follow-up from a prospective, multicentre cohort study
- Hyperbaric oxygen therapy. [Carta]: More hope than hype for future treatment of perianal fistulizing Crohn s disease ?
- Induction therapeutic drug monitoring regimen with infliximab: a simplified evidence-based algorithm for inflammatory bowel disease
- Postoperative complications after deep bowel endometriosis surgery [Carta]: is the surgical technique the only one to blame?
- A novel technique for superficial complicated stomas using the Dacron vascular prosthesis
- Real-world disease activity and sociodemographic, clinical and treatment characteristics of moderate-to-severe inflammatory bowel disease in Brazil
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003272489.pdf | Direct link |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
